TP53 and ovarian carcinoma: In the light of these findings, we aimed to evaluate the clinical significance of ERBB2 expression in a large group of advanced stage ovarian carcinomas, with the application of less stringent criteria of ERBB2 overexpression, and with respect to TP53 status.